EP1119552A1 - Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk 3? humains - Google Patents

Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk 3? humains

Info

Publication number
EP1119552A1
EP1119552A1 EP99970379A EP99970379A EP1119552A1 EP 1119552 A1 EP1119552 A1 EP 1119552A1 EP 99970379 A EP99970379 A EP 99970379A EP 99970379 A EP99970379 A EP 99970379A EP 1119552 A1 EP1119552 A1 EP 1119552A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
solvates
salts
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99970379A
Other languages
German (de)
English (en)
French (fr)
Inventor
Alain Aulombard
Xavier Edmonds-Alt
Vincenzo Proietto
Didier Van Broeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP1119552A1 publication Critical patent/EP1119552A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
EP99970379A 1998-10-09 1999-10-04 Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk 3? humains Withdrawn EP1119552A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812859 1998-10-09
FR9812859A FR2784377B3 (fr) 1998-10-09 1998-10-09 Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant
PCT/FR1999/002355 WO2000021931A1 (fr) 1998-10-09 1999-10-04 Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk3 humains

Publications (1)

Publication Number Publication Date
EP1119552A1 true EP1119552A1 (fr) 2001-08-01

Family

ID=9531536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99970379A Withdrawn EP1119552A1 (fr) 1998-10-09 1999-10-04 Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk 3? humains

Country Status (25)

Country Link
US (1) US6465489B1 (sh)
EP (1) EP1119552A1 (sh)
JP (1) JP2002527423A (sh)
KR (1) KR20010085903A (sh)
CN (1) CN1133622C (sh)
AR (1) AR029148A1 (sh)
AU (1) AU751592B2 (sh)
BR (1) BR9914397A (sh)
CA (1) CA2346729A1 (sh)
CO (1) CO5180555A1 (sh)
DZ (1) DZ2905A1 (sh)
EA (1) EA003613B1 (sh)
EE (1) EE200100214A (sh)
FR (1) FR2784377B3 (sh)
HU (1) HUP0201709A3 (sh)
IL (1) IL142362A0 (sh)
IS (1) IS5897A (sh)
NO (1) NO20011779L (sh)
NZ (1) NZ510779A (sh)
PL (1) PL347910A1 (sh)
SK (1) SK4642001A3 (sh)
TR (1) TR200101030T2 (sh)
TW (1) TW539669B (sh)
WO (1) WO2000021931A1 (sh)
YU (1) YU26001A (sh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068604A2 (en) 2000-03-14 2001-09-20 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
WO2004005256A2 (en) * 2002-07-03 2004-01-15 Glaxo Group Limited Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
US20110144081A1 (en) 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US9554659B2 (en) 2012-10-22 2017-01-31 Uwm Research Foundation, Inc. Infant sleep pod
JPWO2020101017A1 (ja) * 2018-11-15 2021-09-30 国立大学法人九州大学 Ｉｌ−３１介在性疾患の予防又は治療剤及び医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2738819B1 (fr) 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
AU4176997A (en) * 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0021931A1 *

Also Published As

Publication number Publication date
AU751592B2 (en) 2002-08-22
DZ2905A1 (fr) 2004-03-01
US6465489B1 (en) 2002-10-15
PL347910A1 (en) 2002-04-22
IL142362A0 (en) 2002-03-10
CA2346729A1 (en) 2000-04-20
NO20011779L (no) 2001-06-07
HUP0201709A2 (en) 2002-09-28
FR2784377B3 (fr) 2000-11-17
FR2784377A1 (fr) 2000-04-14
KR20010085903A (ko) 2001-09-07
AR029148A1 (es) 2003-06-18
BR9914397A (pt) 2001-06-26
EA003613B1 (ru) 2003-06-26
EA200100299A1 (ru) 2001-10-22
JP2002527423A (ja) 2002-08-27
CN1329594A (zh) 2002-01-02
SK4642001A3 (en) 2001-09-11
NO20011779D0 (no) 2001-04-06
AU5988799A (en) 2000-05-01
WO2000021931A1 (fr) 2000-04-20
HUP0201709A3 (en) 2003-03-28
IS5897A (is) 2001-03-16
NZ510779A (en) 2003-07-25
TR200101030T2 (tr) 2001-08-21
EE200100214A (et) 2002-08-15
CN1133622C (zh) 2004-01-07
CO5180555A1 (es) 2002-07-30
YU26001A (sh) 2003-04-30
TW539669B (en) 2003-07-01

Similar Documents

Publication Publication Date Title
EP0673928B1 (fr) Nouveaux dérivés de la N-(3,4-dichlorophényl-propyl)-pipéridine comme antagonistes sélectifs du récepteur NK3 humain
EP0559538B1 (fr) Sels quaternaires de pipéridines 4-substitués, leur préparation et compositions pharmaceutiques les contenant
EP1156049B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP1019373B1 (fr) Derives de 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidine comme antagonistes selectifs du recepteur nk3 humain
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
FR2861074A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1395582B1 (fr) Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
EP1150970B1 (fr) Derives de (1-phenacy-3-phenyl-3-piperidylethyl)piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
EP1165528B1 (fr) Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2000021931A1 (fr) Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk3 humains
FR2755133A1 (fr) Nouveaux derives d'amides cycliques diversement substitues antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2717478A1 (fr) Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2789389A1 (fr) Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
MXPA01003628A (en) Ureidopiperidine derivatives as selective human nk3
FR2717477A1 (fr) Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010509;LT PAYMENT 20010509;LV PAYMENT 20010509;MK PAYMENT 20010509;RO PAYMENT 20010509;SI PAYMENT 20010509

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI-AVENTIS

17Q First examination report despatched

Effective date: 20060905

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036795

Country of ref document: HK